.png "Global Insight")
An experimental drug that stimulates only a narrow slice of the immune system has, in its first human trial, stopped tumour growth in most patients whose solid cancers had already resisted standard immunotherapy. The drug, invikafusp alfa — known as invika — is not a cure, and the trial is early. But the results, published in Nature Medicine and announced by the National Institutes of Health on October 23, point to a more precise way of rallying the body's defences against cancers that have run out of options.
According to the NIH and Medical Xpress, the study was led by researchers at the NIH, Mass General Brigham and Memorial Sloan Kettering. At the identified optimal dose, disease progression stopped in 16 of 27 participants — 59.3 percent — and four participants, 14.8 percent, saw their targeted tumours shrink by more than 30 percent. Those responses included patients with metastatic colorectal cancer and stage 4 non-small cell lung cancer whose tumours had resisted prior therapies.
Why precision matters
Immunotherapy has transformed cancer treatment, but it has a stubborn limit: many patients benefit only briefly, or not at all. Tumours frequently adapt to immune checkpoint blockade therapies such as pembrolizumab, blunting their long-term effect. Other strategies try to rally T cells — the frontline soldiers of adaptive immunity — but usually do so indiscriminately, switching on immune cells broadly and causing severe side effects in the process.
Invika takes a narrower approach. It is a protein drug engineered to target a specific subset of tumour-infiltrating T cells, expanding those cells without activating the wider immune system. In the trial, participants received treatment every two weeks while researchers tested safety and searched for the optimal dose. The side effects that did appear were mostly flu-like and manageable with medication and supportive care — a meaningful contrast with the severe reactions that broad immune activation can cause.
What the numbers do — and do not — prove
Early-phase trials are designed to answer two questions: is the drug safe, and is there a signal worth pursuing? On both, invika passes its first test. But 27 patients at the optimal dose is a small group, and "disease did not progress" is not the same as "cancer cured." Tumours that stall can resume growing, and early immune activity does not always translate into lasting clinical benefit — a caution the NIH researchers themselves emphasised.
The trial's structure also matters. An initial dose-escalating phase 1 trial enrolled 34 patients with advanced solid tumours and few remaining options, followed by a phase 2 stage. The sponsor, Marengo Therapeutics, has received Fast Track designation from the US Food and Drug Administration to evaluate invika for antigen-rich metastatic colorectal cancer and other solid tumours after previous therapies. Fast Track is a procedural acceleration, not an approval — it means regulators see enough promise to speed up review, not that the drug works.
Where this goes next
The next steps are larger trials that can answer the questions this one cannot: which patients benefit most, how long responses last, and whether the drug works better alone or combined with other therapies. Researchers also need to learn whether the specific T-cell subset invika expands is present in enough tumour types to make the approach broadly useful, or whether it will remain a niche option for certain cancers.
For patients whose tumours have resisted everything else, even a niche option matters. As co-corresponding author James Gulley of the NIH's Center for Cancer Research put it, patients with advanced tumours that do not respond well to immunotherapy often have their backs against the wall, with few options remaining once that point is reached. Invika does not change that picture yet. It offers something rarer in early cancer research: a plausible mechanism, a tolerable safety profile, and a signal strong enough to justify the larger trials that will decide whether it becomes a real treatment.
This article is general information only and is not medical advice. Related health coverage: the Ebola vaccine trial beginning in Congo and Europe's deadliest summer on record.